Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402046 | 0.81 | ALDH1A1 (0.47) | PTGS2KDM4ECYP3A4 | |
| SCHEMBL942835 | 0.81 | PTGS2 (0.64) | PTGS2KDM4ETDP1 | |
| SCHEMBL245135 | 0.73 | NOS3 (0.50) | KDM4E | |
| SCHEMBL13402253 | 0.73 | PTGS2 (0.58) | PTGS2KDM4ETDP1 | |
| SCHEMBL10472323 | 0.71 | PTGS2 (0.50) | PTGS2 | |
| SCHEMBL13458380 | 0.71 | KDM4E (0.51) | PTGS2PTPN1PDE5AKDM4ECYP3A4 | |
| SCHEMBL5355341 | 0.70 | PTGS2 (0.64) | PTGS2KDM4ETDP1 | |
| SCHEMBL30179347 | 0.70 | PTGS2 (0.59) | PTGS2PTPN1KDM4ETDP1 | |
| SCHEMBL172737 | 0.70 | PTGS2 (0.59) | PTGS2PTPN1KDM4ETDP1 | |
| SCHEMBL13402386 | 0.70 | GABRA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754192-B2 | Compositions comprising homogeneously glycosylated erythropoietin | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-06-17 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | EPOR, LIFR, LNPEP | PTGS2 2438/4885PTPN1 920/4885PDE5A 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.